Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2017
Institute for Clinical and Economic Review announces new 13.9 million dollar grant from the Laura and John Arnold Foundation
31 October 2017 - Expanded funding enables ICER value assessments for all newly approved medicines in the US. ...
Posted by Michael Wonder on 12 Oct 2017
Institute for Clinical and Economic Review to evaluate cystic fibrosis treatments in upcoming report
12 October 2017 - Report expected to review tezacaftor, lumacaftor, and ivacaftor (Vertex Pharmaceuticals); Open Input accepted until 27 October. ...
Posted by Michael Wonder on 03 Oct 2017
Institute for Clinical and Economic Review releases draft evidence report on treatments for tardive dyskinesia
2 October 2017 - Public comment period now open until 30 October; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 30 Sep 2017
Institute for Clinical and Economic Review's final report confirms inadequate evidence to compare outcomes of PARP inhibitors for ovarian cancer, highlights poor cost-effectiveness, particularly for maintenance therapy
29 September 2017 - The ICER has issued a final evidence report assessing the comparative clinical effectiveness and value of ...
Posted by Michael Wonder on 11 Sep 2017
Institute for Clinical and Economic Review posts updated economic analyses for PCSK9 inhibitor evolocumab, finds less favourable cost-effectiveness
11 September 2017 - To reflect new clinical trial evidence, updated ICER value-based price benchmark for a year of treatment ...
Posted by Michael Wonder on 09 Sep 2017
Should value frameworks take a ‘societal perspective’?
6 September 2017 - In 1996, the U.S. Panel on Cost-Effectiveness in Health and Medicine recommended that analysts conducting cost-effectiveness ...
Posted by Michael Wonder on 31 Aug 2017
Institute for Clinical and Economic Review report finds inadequate evidence to compare PARP inhibitors across key ovarian cancer indications
30 August 2017 - The ICER has released an evidence report assessing the comparative clinical effectiveness and value of three ...
Posted by Michael Wonder on 12 Aug 2017
Institute for Clinical and Economic Review to evaluate comparative clinical effectiveness and value of emicizumab for haemophilia A
11 August 2017 - Open input period now open until 6 September 2017. ...
Posted by Michael Wonder on 26 Jul 2017
Institute for Clinical and Economic Review announces potential topics for review in 2018
26 July 2017 - Tentative list includes drugs for migraines, haemophilia, and cystic fibrosis. ...
Posted by Michael Wonder on 25 Jul 2017
Dr Steve Pearson on using health technology assessment to guide decision making
23 July 2017 - Health technology assessment is a tool that helps to objectively evaluate evidence, which levels the playing field ...
Posted by Michael Wonder on 17 Jul 2017
Institute for Clinical and Economic Review's final evidence report finds prices of anabolic agents for osteoporosis too high, not aligned with potential benefits over other treatments
17 July 2017 - Policy recommendations highlight need for prices to align with clinical benefit, clear guidelines to define highest ...
Posted by Michael Wonder on 13 Jul 2017
ICER releases draft evidence report reviewing olaparib, rucaparib, and niraparib for ovarian cancer
12 July 2017 - Public comment period now open until 9 August; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 20 Jun 2017
When cholesterol drugs cost $14,000, an insurance tug-of-war
19 June 2017 - Patients struggle to obtain PCSK9 inhibitors, a powerful class of drugs that lower bad cholesterol in difficult ...
Posted by Michael Wonder on 17 Jun 2017
Institute for Clinical and Economic Review report finds inadequate evidence to distinguish between anabolic therapies for osteoporosis
16 June 2017 - Cost-effectiveness analyses find prices too high to align with added benefit to patients. ...
Posted by Michael Wonder on 13 Jun 2017
Institute for Clinical and Economic Review’s “new evidence update” on PCKS9 inhibitors highlights lack of mortality benefit with evolocumab
13 June 2017 - Newly released clinical trial data show expected reductions in stroke and heart attack, but mortality benefit ...